<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7120377/results/search/test_trace/results.xml">
  <result pre="with these viruses may be indistinguishable from that associated with" exact="infection" post="with classic hepatotropic viruses. The presentation ranges from mild"/>
  <result pre="the classic hepatotropic viruses are not indicative of an active" exact="infection" post="[1]. In the present chapter, we review the clinical"/>
  <result pre="severe systemic infection. Antiviral agents have a role in the" exact="treatment" post="of immune-compromised patients and in immune-competent patients who present"/>
  <result pre="with these viruses may be indistinguishable from that associated with" exact="infection" post="with classic hepatotropic viruses. The presentation ranges from a"/>
  <result pre="the classic hepatotropic viruses are not indicative of an active" exact="infection" post="[1]. In the present chapter, we review the clinical"/>
  <result pre="fever virus, Reovirus 3 Table 12.2 Clinical features, diagnosis, and" exact="treatment" post="summary table Virus Population at risk Clinical and laboratory"/>
  <result pre="Clinical and laboratory features Acute liver failure Unique complications Diagnostic" exact="tests" post="Treatment Effective antiviral medication EBV IC Age &amp;gt;30 (esp."/>
  <result pre="severe end organ disease IC—antivirals ± IVIG Organ transplant recipients—prophylactic vs. preemptive" exact="treatment" post="Ganciclovir Valganciclovir Foscarnet Cidofovir CMV hyperimmune globulin Leflunomide HSV"/>
  <result pre="rash Rare More common in immunocompromised individuals Graft loss Viral" exact="isolation" post="from skin lesions HSV PCR (blood and tissue) Liver"/>
  <result pre="these proteins allows the virus to establish different forms of" exact="infection" post="[2]. Cell entry and translocation of EBV particles to"/>
  <result pre="translocation of EBV particles to the nucleus is confirmed by" exact="detection" post="of the EBV genome in isolated nuclei [3]. While"/>
  <result pre="strategies to evade immune system recognition and to establish latent" exact="infection" post="in memory B cells, where it resides lifelong without"/>
  <result pre="a small percentage of latently infected B cells [5]. EBV" exact="infection" post="is a common and lifelong infection affecting over 90"/>
  <result pre="B cells [5]. EBV infection is a common and lifelong" exact="infection" post="affecting over 90 % of humans worldwide. The virus"/>
  <result pre="in saliva [1, 6]. Transmission of EBV usually occurs by" exact="contact" post="with oral secretions. Diagnosis of EBV infection is based"/>
  <result pre="usually occurs by contact with oral secretions. Diagnosis of EBV" exact="infection" post="is based on clinical features and on laboratory and"/>
  <result pre="(EBVNA), and soluble complement-fixing antigens (anti-S) are used for viral" exact="detection" post="[1]. The &quot;monospot&quot; test that detects heterophil antibodies is"/>
  <result pre="focal hepatic necrosis or fatty infiltration [1, 7]. Specifically, the" exact="diagnosis" post="of EBV hepatitis is established based on the combination"/>
  <result pre="cells hamper pathogen entry at mucosal sites, thus restricting EBV" exact="infection" post="until the adaptive immunity establishes viral immune control [9]."/>
  <result pre="B-cell transformation, decreasing their proliferation during the first week following" exact="infection" post="[4, 10]. IFN-γ also promotes an EBV-specific adaptive immune"/>
  <result pre="burden until virus-specific T cells are able to eliminate the" exact="infection" post="or maintain viral titers at low levels. Innate immunity"/>
  <result pre="Toll-like receptor (TLR) activation has downstream effects during primary EBV" exact="infection" post="that favor viral latency or reactivation and facilitate immune"/>
  <result pre="Exosomes play a role during the early phases of EBV" exact="infection" post="and also involve innate immunity-related cell types that are"/>
  <result pre="the reduced phagocytic activity observed in EBV-infected monocytes [3]. EBV" exact="infection" post="inhibits the functional ability of macrophages to respond to"/>
  <result pre="CTLs are major determinants in the control of acute EBV" exact="infection" post="and are directed against both lytic and latent antigens"/>
  <result pre="About half of the total CD8+ T cells in acute" exact="infection" post="are specific for a single lytic EBV epitope, and"/>
  <result pre="confirming that CTLs are the most important cells for limiting" exact="infection" post="in the convalescent phase of virus infection. In lytic"/>
  <result pre="the humoral response controls viral spread in late phases of" exact="infection" post="[21]. EBV stimulates strong humoral responses to lytic cycle"/>
  <result pre="to nucleocapsid and envelope proteins are detectable in primary EBV" exact="infection" post="[4]. IgG responses to immediate-early and early lytic cycle"/>
  <result pre="lymphoma, and post-transplant lymphoproliferative disorder (PTLD) [22, 23]. Primary EBV" exact="infection" post="takes place in the oropharyngeal region, to which the"/>
  <result pre="virus is conveyed by saliva droplets from infected individuals. Primary" exact="infection" post="leads to transient viremia followed by a strong T-cell"/>
  <result pre="by a strong T-cell adaptive immune response that holds the" exact="infection" post="latent in immunocompetent individuals [22, 24]. If infection is"/>
  <result pre="holds the infection latent in immunocompetent individuals [22, 24]. If" exact="infection" post="is delayed to adolescence or adulthood, it can cause"/>
  <result pre="occasional reports of fatal acute fulminant hepatitis. Abnormal liver blood" exact="tests" post="are common in EBV infection and occur in up"/>
  <result pre="fulminant hepatitis. Abnormal liver blood tests are common in EBV" exact="infection" post="and occur in up to 90 % of patients,"/>
  <result pre="lower than that encountered in acute viral hepatitis [1]. The" exact="diagnosis" post="is suggested by the presence of a lymphocytosis and/or"/>
  <result pre="are incidentally or intentionally in the liver. Chronic active EBV" exact="infection" post="(CAEBV) may result from a disturbance in the host–virus"/>
  <result pre="by chronic severe illness, which begins as a primary EBV" exact="infection" post="associated with elevated transaminases, abnormal EBV serology, suggestive histopathological"/>
  <result pre="with elevated transaminases, abnormal EBV serology, suggestive histopathological features, and" exact="detection" post="of viral genome in the liver tissue. Evidence of"/>
  <result pre="increased LDH levels, mild splenomegaly, and thrombocytopenia, can support the" exact="diagnosis" post="[2, 31]. CAEBV may also progress to a chronic"/>
  <result pre="While the existence of acute mononuclear hepatitis during primary EBV" exact="infection" post="is accepted, skepticism has been expressed as to the"/>
  <result pre="liver disease caused by a major hepatotropic virus, a co-EBV" exact="infection" post="was suggested. In a cohort of patients with chronic"/>
  <result pre="with chronic hepatitis B and C, patients with reactivated EBV" exact="infection" post="had lower levels of HBV DNA and higher mean"/>
  <result pre="spectrum of lymphoproliferative diseases occurring in the post-transplantation setting. EBV" exact="infection" post="is the main cause of PTLD. The incidence of"/>
  <result pre="up to 50 %. In the pediatric population, post-transplant primary" exact="infection" post="within 3 months of OLT was associated with sustained"/>
  <result pre="within 3 months of OLT was associated with sustained EBV" exact="detection" post="and increased the risk of the late occurrence of"/>
  <result pre="polymerase chain reaction (PCR) can assist in the surveillance and" exact="diagnosis" post="of PTLD, although its specificity for the diagnosis is"/>
  <result pre="surveillance and diagnosis of PTLD, although its specificity for the" exact="diagnosis" post="is only 50 % [39]. Post-transplantation patients should be"/>
  <result pre="the peripheral blood with the purpose of detecting active EBV" exact="infection" post="early and instituting preemptive therapy prior to the development"/>
  <result pre="consists of etoposide-based chemotherapy and hematopoietic stem cell transplantation. Early" exact="treatment" post="of primary EBV infection in these patients (prior to"/>
  <result pre="and hematopoietic stem cell transplantation. Early treatment of primary EBV" exact="infection" post="in these patients (prior to development of HLH) may"/>
  <result pre="patients (prior to development of HLH) may be comprised of" exact="treatment" post="with anti-CD20 antibodies in combination with antivirals (acyclovir or"/>
  <result pre="load in these patients. Treatment of EBV Hepatitis Primary EBV" exact="infection" post="is subclinical in the majority of immunocompetent individuals; it"/>
  <result pre="adults. It is generally self-limiting; therefore, in immunocompetent individuals, symptomatic" exact="treatment" post="alone is recommended. This includes rest, adequate hydration and"/>
  <result pre="debatable. However, it is suggested as an adjunct to steroid" exact="treatment" post="[45], especially in cases of refractory disease [46]. Several"/>
  <result pre="not reduce viremia or symptoms. Ganciclovir was effective in the" exact="treatment" post="of EBV hepatitis in a small number of children"/>
  <result pre="oral pro-drug of ganciclovir, has been successfully used in the" exact="treatment" post="of severe acute EBV hepatitis (900 mg × 2/daily for 15"/>
  <result pre="others), immunosuppressive therapy, and HIV/AIDS. In these patients, primary EBV" exact="infection" post="should be treated preemptively with ex vivo-generated EBV-specific CTLs"/>
  <result pre="of the beta herpesviridae family. The cellular response to CMV" exact="infection" post="is characterized by cytomegaly and a spectrum of prominent"/>
  <result pre="of clinical syndromes associated with CMV disease ranges from asymptomatic" exact="infection" post="to life-threatening congenital CMV syndrome in neonates to infectious"/>
  <result pre="[1]. Serologic studies of CMV-IgM antibodies are helpful for the" exact="diagnosis" post="of primary infections. Viral culture techniques use the &quot;shell"/>
  <result pre="early antigen or CMV DNA increase sensitivity for detecting CMV" exact="infection" post="in blood and end organ tissue. To clearly establish"/>
  <result pre="in blood and end organ tissue. To clearly establish the" exact="diagnosis" post="of active CMV infection, it is necessary to have"/>
  <result pre="Distinct pathologic findings on liver biopsy are important for the" exact="diagnosis" post="of CMV hepatitis, especially in immunocompromised hosts. Giant multinucleated"/>
  <result pre="asymptomatic or associated with a mild IM syndrome. Symptomatic CMV" exact="infection" post="in non-immunocompromised hosts has traditionally been considered to display"/>
  <result pre="viruses are sequestered in a non-replicative state. Persons with latent" exact="infection" post="and intact immune systems have no symptoms but exhibit"/>
  <result pre="with massive necrosis [88]. The morbidity and mortality that CMV" exact="infection" post="may cause in immunocompetent hosts were recently reviewed in"/>
  <result pre="In immunocompromised patients, CMV disease results either from a primary" exact="infection" post="or, more commonly, from reactivation of a latent infection"/>
  <result pre="primary infection or, more commonly, from reactivation of a latent" exact="infection" post="[1, 52]. Disseminated CMV infections in immunocompromised patients with"/>
  <result pre="encephalitis, pneumonitis, hepatitis, uveitis, retinitis, colitis, and graft rejection. CMV" exact="infection" post="affecting the human embryo, a host with immature immunologic"/>
  <result pre="to blindness [52]. CMV is the most common opportunistic viral" exact="infection" post="in AIDS patients, causing retinitis, central nervous system infections,"/>
  <result pre="therapy. Hepatitis is the most frequent organ-specific complication of CMV" exact="infection" post="after liver transplantation, affecting 10 % of recipients and"/>
  <result pre="patients (26 % vs. 9 %, respectively). In these cases," exact="infection" post="occurs as a consequence of reactivation rather than primary"/>
  <result pre="infection occurs as a consequence of reactivation rather than primary" exact="infection" post="[1]. Treatment of CMV Infection The current opinion is"/>
  <result pre="Treatment of CMV Infection The current opinion is that CMV" exact="infection" post="in immunocompetent patients does not require treatment [52]. Data"/>
  <result pre="is that CMV infection in immunocompetent patients does not require" exact="treatment" post="[52]. Data on a need for antiviral treatment in"/>
  <result pre="not require treatment [52]. Data on a need for antiviral" exact="treatment" post="in immunocompetent patients with severe CMV infection is conflicting."/>
  <result pre="need for antiviral treatment in immunocompetent patients with severe CMV" exact="infection" post="is conflicting. The improvement observed in some treated patients"/>
  <result pre="disease and thus cannot be attributed with certainty to a" exact="treatment" post="effect [45]. For severe cases, particularly in patients with"/>
  <result pre="cell-mediated immunity, therapy can be life-saving [1]. Drugs approved for" exact="treatment" post="of CMV disease include ganciclovir, valganciclovir, foscarnet, and cidofovir."/>
  <result pre="resistant viral strains [45]. CMV in Liver Transplant Recipients CMV" exact="infection" post="is a common complication following liver transplantation and contributes"/>
  <result pre="indistinguishable from acute allograft rejection [56]. The availability of sensitive" exact="tests" post="for the rapid detection of CMV in the blood"/>
  <result pre="rejection [56]. The availability of sensitive tests for the rapid" exact="detection" post="of CMV in the blood may obviate the need"/>
  <result pre="obviate the need for a liver biopsy to differentiate CMV" exact="infection" post="from rejection. However, in many cases, a liver biopsy"/>
  <result pre="transplantation, compared to 35 % of patients with asymptomatic CMV" exact="infection" post="and 17 % of those who did not develop"/>
  <result pre="and 17 % of those who did not develop CMV" exact="infection" post="[64]. CMV infection is an independent predictor of mortality"/>
  <result pre="of those who did not develop CMV infection [64]. CMV" exact="infection" post="is an independent predictor of mortality after solid organ"/>
  <result pre="drugs are administered early to halt progression of the asymptomatic" exact="infection" post="to full-blown clinical disease [67]. Preemptive therapy with oral"/>
  <result pre="in CMV disease and a 40 % reduction in CMV" exact="infection" post="[68]. The use of acyclovir as anti-CMV prophylaxis after"/>
  <result pre="of post-transplant CMV disease [69]. The current recommendation for antiviral" exact="treatment" post="of CMV disease after liver transplantation is intravenous ganciclovir"/>
  <result pre="degree of pharmacologic immunosuppression [78]. Valganciclovir is a possible oral" exact="treatment" post="for mild to moderate disease [78]. In cases of"/>
  <result pre="to moderate disease [78]. In cases of ganciclovir-resistant CMV disease," exact="treatment" post="options include foscarnet, cidofovir, CMV hyperimmune globulins, or leflunomide"/>
  <result pre="be detected in 14 % of healthy adults with genital" exact="infection" post="[79]. Fulminant hepatitis with more than 100-fold rise in"/>
  <result pre="in bilirubin [1]. Liver biopsy is essential to establish the" exact="diagnosis" post="of HSV hepatitis. It shows focal, sometimes extensive, hemorrhagic,"/>
  <result pre="identified at the margins of the foci of necrosis. The" exact="diagnosis" post="is confirmed by detection of HSV DNA sequences by"/>
  <result pre="of the foci of necrosis. The diagnosis is confirmed by" exact="detection" post="of HSV DNA sequences by molecular techniques [1]. In"/>
  <result pre="women, it is observed in the context of disseminated primary" exact="infection" post="during the third trimester and presenting as fulminant hepatitis."/>
  <result pre="cases; thus, many cases are not diagnosed until autopsy. Early" exact="diagnosis" post="and treatment with antiviral therapy may reverse an otherwise"/>
  <result pre="many cases are not diagnosed until autopsy. Early diagnosis and" exact="treatment" post="with antiviral therapy may reverse an otherwise fatal process"/>
  <result pre="antiviral therapy may reverse an otherwise fatal process [1]. The" exact="treatment" post="of choice in these patients is early high-dose acyclovir"/>
  <result pre="[81, 82]. Recurrence was not observed, suggesting that disseminated HSV" exact="infection" post="should not be an absolute contraindication for transplantation in"/>
  <result pre="foscarnet, ganciclovir, and cidofovir [86]. Varicella Zoster Virus Primary varicella" exact="infection" post="is usually benign with mild transient elevation in liver"/>
  <result pre="and even ALF in immune-competent adults. In transplanted patients, primary" exact="infection" post="can present with an aggressive liver disease [1]. Such"/>
  <result pre="infection can present with an aggressive liver disease [1]. Such" exact="infection" post="may occur in the immediate postoperative period or up"/>
  <result pre="usually associated with rapid onset and fatal hepatitis [87]. Serologic" exact="testing" post="is of little value in immunocompromised patients. Confirmation of"/>
  <result pre="testing is of little value in immunocompromised patients. Confirmation of" exact="diagnosis" post="is made through isolation of VZV from skin lesions"/>
  <result pre="value in immunocompromised patients. Confirmation of diagnosis is made through" exact="isolation" post="of VZV from skin lesions or from the affected"/>
  <result pre="patients, associated with increased mortality [89]. Fatal cases of adenovirus" exact="infection" post="with fulminant hepatitis were reported in immunosuppressed adults [90]."/>
  <result pre="available, and cidofovir has been recently suggested as an optional" exact="treatment" post="[1]. Additional Viruses That May Cause Hepatitis Several viruses"/>
  <result pre="involve the liver as a part of an acute viral" exact="infection" post="(Table 12.1). This infection may manifest as mild hepatitis"/>
  <result pre="a part of an acute viral infection (Table 12.1). This" exact="infection" post="may manifest as mild hepatitis and rarely as severe"/>
  <result pre="cytomegalovirus-specific CD8(+) T cell responseJ Immunol200216854556412023339 21.HislopADTaylorGSSauceDRickinsonABCellular responses to viral" exact="infection" post="in humans: lessons from Epstein-Barr virusAnnu Rev Immunol20072558761710.1146/annurev.immunol.25.022106.14155317378764 22.CohenJIEpstein-Barr"/>
  <result pre="immunocompetent subjectMed Mal Infect200636396810.1016/j.medmal.2006.03.00216876362 29.ChibaTGotoSYokosukaOImazekiFTanakaMFukaiKTakahashiYet al.Fatal chronic active Epstein-Barr virus" exact="infection" post="mimicking autoimmune hepatitisEur J Gastroenterol Hepatol200416225810.1097/00042737-200402000-0001715075999 30.BabelNSchwarzmannFPrangNJaegerMWolfHKernFVolkHDet al.Association between"/>
  <result pre="autoimmune hepatitisEur J Gastroenterol Hepatol200416225810.1097/00042737-200402000-0001715075999 30.BabelNSchwarzmannFPrangNJaegerMWolfHKernFVolkHDet al.Association between Epstein-Barr virus" exact="infection" post="and late acute transplant rejection in long-term transplant patientsTransplantation200172736910.1097/00007890-200108270-0003111544441"/>
  <result pre="following liver transplantationCurr Opin Organ Transplant2011162748010.1097/MOT.0b013e328346571521467936 40.D’AntigaLDel RizzoMMengoliCCilloUGuarisoGZancanLSustained Epstein-Barr virus" exact="detection" post="in paediatric liver transplantation. Insights into the occurrence of"/>
  <result pre="control in infectious mononucleosis. Cochrane Database Syst Rev. 2006;CD004402. 45.RafailidisPIMavrosMNKapaskelisAFalagasMEAntiviral" exact="treatment" post="for severe EBV infections in apparently immunocompetent patientsJ Clin"/>
  <result pre="Virol201049151710.1016/j.jcv.2010.07.00820739216 46.PisapiaRMarianoARiandaATestaAOlivaAVincenziLSevere EBV hepatitis treated with valganciclovirInfection201341251410.1007/s15010-012-0303-022837057 47.AdamsLADeboerBJeffreyGMarleyRGarasGGanciclovir and the" exact="treatment" post="of Epstein-Barr virus hepatitisJ Gastroenterol Hepatol20062117586010.1111/j.1440-1746.2006.03257.x16984606 48.FeranchakAPTysonRWNarkewiczMRKarrerFMSokolRJFulminant Epstein-Barr viral"/>
  <result pre="Transpl Surg199844697610.1002/lt.5000406129791157 49.OkanoMGrossTGAdvanced therapeutic and prophylactic strategies for Epstein-Barr virus" exact="infection" post="in immunocompromised patientsExpert Rev Anti Infect Ther200754031310.1586/14787210.5.3.40317547505 50.StarasSADollardSCRadfordKWFlandersWDPassRFCannonMJSeroprevalence of"/>
  <result pre="in immunocompromised patientsExpert Rev Anti Infect Ther200754031310.1586/14787210.5.3.40317547505 50.StarasSADollardSCRadfordKWFlandersWDPassRFCannonMJSeroprevalence of cytomegalovirus" exact="infection" post="in the United States, 1988–1994Clin Infect Dis20064311435110.1086/50817317029132 51.KunnoAAbeMYamadaMMurakamiKClinical and"/>
  <result pre="features of cytomegalovirus hepatitis in previously healthy adultsLiver1997171293210.1111/j.1600-0676.1997.tb00794.x9249726 52.RafailidisPIMourtzoukouEGVarbobitisICFalagasMESevere cytomegalovirus" exact="infection" post="in apparently immunocompetent patients: a systematic reviewVirol J200854710.1186/1743-422X-5-4718371229 53.GaliatsatosPShrierILamoureuxESzilagyiAMeta-analysis"/>
  <result pre="experience in a community-based, university-affiliated hospitalGastroenterol Hepatol (N Y)20128230922723754 56.RazonableRRCytomegalovirus" exact="infection" post="after liver transplantation: current concepts and challengesWorld J Gastroenterol20081448496010.3748/wjg.14.484918756591"/>
  <result pre="of late-onset cytomegalovirus (CMV) disease and other sequelae of CMV" exact="infection" post="in organ transplant recipientsClin Infect Dis200847296710.1086/58957718564941 60.ArthursSKEidAJPedersenRADierkhisingRAKremersWKPatelRRazonableRRDelayed-onset primary cytomegalovirus"/>
  <result pre="randomised controlled trialsLancet200536521051510.1016/S0140-6736(05)66553-115964447 69.EidAJRazonableRRNew developments in the management of cytomegalovirus" exact="infection" post="after solid organ transplantationDrugs2010709658110.2165/10898540-000000000-0000020481654 70.BadleyADSeabergECPoraykoMKWiesnerRHKeatingMRWilhelmMPWalkerRCet al.Prophylaxis of cytomegalovirus infection"/>
  <result pre="cytomegalovirus infection after solid organ transplantationDrugs2010709658110.2165/10898540-000000000-0000020481654 70.BadleyADSeabergECPoraykoMKWiesnerRHKeatingMRWilhelmMPWalkerRCet al.Prophylaxis of cytomegalovirus" exact="infection" post="in liver transplantation: a randomized trial comparing a combination"/>
  <result pre="The Oral Ganciclovir International Transplantation Study Group [corrected]Lancet199735017293310.1016/S0140-6736(97)05535-99413463 72.LautenschlagerICMV infection," exact="diagnosis" post="and antiviral strategies after liver transplantationTranspl Int20092210314010.1111/j.1432-2277.2009.00907.x19619175 73.WattKVeldtBCharltonMA practical"/>
  <result pre="transplantationTranspl Int20092210314010.1111/j.1432-2277.2009.00907.x19619175 73.WattKVeldtBCharltonMA practical guide to the management of HCV" exact="infection" post="following liver transplantationAm J Transplant2009917071310.1111/j.1600-6143.2009.02702.x19538491 74.SinghNWannstedtCKeyesLWagenerMMGayowskiTCacciarelliTVIndirect outcomes associated with"/>
  <result pre="a call for empiric therapyDig Dis Sci200045239940410.1023/A:100569921081611258565 81.GloriosoDVMolloyPJVan ThielDHKaniaRJSuccessful empiric" exact="treatment" post="of HSV hepatitis in pregnancy. Case report and review"/>
  <result pre="case report and review of the literatureAm J Med199088778010.1016/0002-9343(90)90133-X2403757 88.AlfordCAAcyclovir" exact="treatment" post="of herpes simplex virus infections in immunocompromised humans. An"/>
 </snippets>
</snippetsTree>
